Amgen Inc vs. Maze Therapeutics, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| AMGN | MAZE | |
|---|---|---|
| Market Cap | $212.55 billion | $1.24 billion |
| Revenue (TTM) | $38.09 billion | $20.00 million |
| Net Income (TTM) | $8.74 billion | $-133,590,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | MAZE | |
|---|---|---|
| P/E Ratio | 25.26 | — |
| Price / Book | 18.19 | 2.74 |
| Price / Sales | 5.58 | 62.19 |
AMGN and MAZE split the valuation factors evenly.
Profitability
| AMGN | MAZE | |
|---|---|---|
| Net Margin | 22.95% | -667.95% |
| Return on Equity | 74.80% | -29.48% |
AMGN leads on 2 of 2 profitability factors.
Dividend
| AMGN | MAZE | |
|---|---|---|
| Dividend Yield | 2.48% | — |
| Payout Ratio | 62.61 | — |
AMGN and MAZE split the dividend factors evenly.
Risk & Sentiment
| AMGN | MAZE | |
|---|---|---|
| Short Interest | 1.66% | 2.15% |
AMGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, MAZE overview, MAZE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.